Malignant peripheral nerve sheath tumors (MPNST) – Clinicopathological study and treatment outcome of twenty-four cases
© Kar et al; licensee BioMed Central Ltd. 2006
Received: 09 September 2005
Accepted: 22 August 2006
Published: 22 August 2006
Malignant peripheral nerve sheath tumor (MPNST) is biologically an aggressive tumor for which the treatment of choice is the surgery. We reviewed the clinical profile, diagnostic methods, treatment patterns, and outcome of twenty-four MPNST patients in this study.
Patients and methods
A retrospective analysis of 24 MPNST patients, treated from 1994 to 2002, in the department of Surgical Oncology at All India Institute of Medical Sciences, New Delhi, was done. A combination of gross, histopathological and immunohistochemical findings, and proliferation markers (MIB1) were considered for diagnosis and grade of the MPNST. Survival analysis was done by the Kaplan-Meier method and differences were evaluated with the log-rank test. Multivariate analysis was carried out by using Cox's proportional hazards model by using SPSS (Version 9, Chicago, Illinois) software.
MPNST constituted 12% of all soft tissue sarcomas, where 21% (5/24) of patients had associated Von Recklinghausen's disease (VRHD). A higher incidence of male preponderance and multifocal MPNST were noted in the present series. At a mean follow-up of 38 months, 13 (54 %) patients had relapse of disease and 5-year over all and disease free survival were 58% and 35% respectively. In univariate analysis, sex (p = 0.05), tumor depth (p < 0.03), and cellular differentiation (p < 0.002) were shown to be adverse prognostic factors for disease free survival and sex (p = 0.04), cellular differentiation (p < 0.0004), and tumor grade (p = 0.05) for overall survival. However, in multivariate analysis, cellular differentiation (p < 0.005) and tumor grade (p < 0.01) emerged as independent prognostic factors for both disease free and overall survival, respectively. Postoperative radiotherapy (RT) has shown a definite role in both disease free and overall survival in this study.
MPNSTs constituted a significant proportion (12%) of soft tissue sarcoma in our medical center. Heterogeneous differentiation and multifocality of the tumor were few distinct features of MPNST. Sex and cellular differentiation were noticed as the new adverse prognostic factors and adjuvant radiotherapy has been proved to be a significant treatment tool in the current series.
Malignant peripheral nerve sheath tumor (MPNST) is a rare variety of soft tissue sarcoma of ectomesenchymal origin [1, 2]. World Health organization (WHO) coined the term MPNST replacing previous heterogeneous and often confusing terminology, such as malignant schwannoma, malignant neurilemmoma, and neurofibrosarcoma, for tumors of neurogenic origin and similar biological behavior [3, 4]. These tumors often create diagnostic problems because of their cellular origin and histopathological similarities with other spindle cell sarcomas like monophasic synovial sarcoma, leiomyosarcoma and fibrosarcoma . They arise from a major or minor peripheral nerve branches  or sheath of peripheral nerve fibers [7, 8]. These tumors may arise spontaneously in adult patients, although 5% to 42% of MPNST have an association with multiple neurofibromatosis Type-I [9–12]. Thus, a combination of gross, histopathological, and immunohistochemical studies are used for diagnosing these tumors. Another interesting clinical feature of this tumor is multifocality and development of second primary tumors of same histology . Surgery is the main stay of treatment of this tumor though they are biologically aggressive in nature [5, 12, 13]. In this article, we reviewed the case records of the patients with malignant peripheral nerve sheath tumors to investigate their clinico-pathological features, treatment outcome, survival, and prognostic factors.
Patients and methods
A retrospective analysis of MPNST patients treated in January 1994 to December 2002 in the Surgical Oncology unit at All India Institute of Medical Sciences, New Delhi was performed. The source of the data was a soft tissue sarcoma database. Twenty-four out of 200 soft tissue sarcoma patients had MPNST. The clinical details, including the presence or absence of VRHD , the histopathology, treatment details, and follow-up were analyzed. Pretreatment evaluation included core needle biopsy or incision and/or excision biopsy for the tissue diagnosis. Extent and stage of the disease was evaluated by the contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI). Patients with small (<5 cm) and subcutaneously located tumors underwent no imaging. All patients underwent surgical excision as the primary therapy and histopathological examination and immunohistochemical staining confirmed the final diagnosis. Adjuvant radiotherapy and chemotherapy was decided on the basis of the size (>5 cm), depth (deep seated), grade (high), and recurrence of the tumor. After completion of therapy all patients were followed-up every 3 monthly on regular basis. Survival was calculated from the date of diagnosis to the date of last follow-up or death. The details of local and systemic recurrences and second primaries were also analyzed. Development of a new sarcoma of same histology in a different anatomical area was taken as second primary or multifocal MPNST.
Survival analysis was done by the Kaplan-Meier method and differences were evaluated with the log-rank test. Multivariate analysis was carried out by using Cox's proportional hazards model.
Anatomical site distribution of the MPNST.
Site of Tumor
Head and neck
Chest wall & trunk
The following criteria were used for the histological diagnosis of MPNST – a) gross fusiform tumors in relation to nerves, b) microscopic features of spindle cell with fascicular pattern and varying degrees of mitosis, necrosis and tumor calcification, c) presence of associated benign neurofibroma or schwannanian cells, and d) positive immunohistochemical staining for S-100 protein, neuron specific enolase (NSE) and others like actin, cytokeratin (CK), smooth muscle actins (SMA), desmin, and vimentin to differentiate from other spindle cell sarcomas. The tumors were classified as low and high grade on the basis of their cellular differentiation, mitotic count, tumor necrosis [15, 16] and expression of MIB-1 proliferation marker [17, 18]. Tumor necrosis was evaluated with scoring as 0, 1, and 2, depending on the percentage of necrosis as 0%, <50%, and >50% presence, respectively. Mitosis rate is also evaluated like wise as 0, 1, and 2, depending on numbers as <5, 5–10, and >10 per 10 hyper power field (HPF), respectively. More than 5 mitotic rates per 10 HPF have been considered as high grade tumor as single mitotic figure may be significant in a tumor with hypercellularity and nuclear atypia . The significance of the mitoses depends on the prognostic value of increased cell proliferation. Tumor necrosis scoring was 0 in 14 patients, 1 in 6 and 2 in 4 patients, respectively, while mitotic rate was 0 in 4, 1 in 8, and 2 in 12 patients, respectively. A >5% cellular staining of MIB-1 proliferation marker has been considered as high grade tumors [17, 18]. The MIB-1 proliferation marker has been done in twenty cases, where >5% staining of cells shown a correlation with the high-grade tumors, while <5% had shown low grade MPNST. Preoperative tissue diagnosis of malignant nerve sheath tumor could be made in 15 (62.5%) patients on biopsy specimens and the remaining were diagnosed as unclassified malignant mesenchymal tumors. In the final histopathology, all patients were diagnosed as malignant peripheral nerve sheath tumor. S-100 immunohistochemical stains were used in twenty cases, of these, fifteen cases (63%) showed strong focal positivity. Other cases were supported by exclusion method of other soft tissue sarcomas by various other immunohistochemical stains. Fifteen patients (62.5%) were categorized as having high-grade and the remaining 9 (37.5%) as low-grade MPNST, on the basis of above pathological parameters. A peculiar proliferation of tumor in the sub-endothelial zones of vessels with neoplastic cells herniation into vessel lumen and proliferation of small vessels in the walls of large vessels have been noticed in our series, which are very characteristic features to designate the tumor as MPNST. In our study, five patients (21%) have shown divergent differentiation of MPNST with heterotrophic such as rhabdoid, chondroid, myoid, epitheloid and osteoid elements in each case, respectively. We encountered some rare pathological findings, such as skeletal muscle entrapment and squamous differentiation, in our series. Size of the tumor ranged from 4 to 24 cm in greatest diameter (mean 10.83 cm), where twenty-two had more than 5 cm size and 8 had more than 10 cm tumor. Two patients had positive tumor resection margin after surgery.
Curative surgery was performed in all 24 cases in the form of wide local excision in 17 cases, amputation or disarticulation in 5 cases and two patients had pelvic exenteration for large pelvic MPNST. Among the 15 patients with extremity MPNST limb salvage surgery was performed in 10, and the remaining 5 had amputations or disarticulation either for primary or recurrent tumor with neuro-vascular encasement and extensive soft tissue with bone involvement. In the current study, 8 out of 24 patients required radical surgery and 16 required conservative surgical procedures. The overall limb salvage rate was 67%. In view of the size (>5 cm), location, and grade, postoperative adjuvant radiotherapy, ranging from 54 to 62 Gy (median dose 58 Gy), was given to 16 patients. Three patients in the radical surgery group and 13 in the conservative surgery group received postoperative radiotherapy. One patient with a Head and Neck MPNST, which was of rhabdoid differentiation (malignant triton tumor), was treated by commando operation and given adjuvant postoperative radiotherapy and chemotherapy. Two patients had disarticulation for their regional recurrence of the disease, with one of these finally succumbing to systemic relapse. All systemic relapse patients received palliative chemotherapy, as no patient was suitable for curative resection.
Sex, tumor depth, VRHD, tumor necrosis, mitotic rate, cellular differentiation, and tumor grade, heterogeneous differentiation of tumor, radiotherapy treatment, and relapse of the disease were studied for prognostic factors.
Prognostic factors affecting disease free survival and overall survival in univariate analysis.
0.92 – 12.93
2. Tumor depth
5.3 – 9.4
0.28 – 3.9
4. Tumour Necrosis
0.2 – 10.4
5. Tumor mitosis
6. Cellular differentiation
2.01 – 111.75
7. Tumor grade
0.14 – 1.51
8. Heterogeneous differentiation
0.14 – 1.48
0.76 – 8.42
0.94 – 13.27
2. Tumor depth
0.4 – 1.18
0.18 – 4.08
4. Tumor Necrosis
5. Tumor Mitosis
6. Cellular differentiation
2.44 – 334.28
7. Tumor grade
0.94 – 4.68
8. Heterogeneous differentiation
0.15 – 1.95
0.10 – 1.28
0.3 – 2.61
Prognostic factors affecting disease free survival and overall survival in multivariate analysis.
1. Cellular differentiation
4.20 – 463.30
1. Tumor Grade
1.41 – 3.07
MPNST is a very rare tumor, with an incidence of 1 per 1,00,000 population and whichconstitutes between 3 to 10% of all soft tissue sarcomas. Hence, this entity is often managed as a sub-category of soft tissue sarcomas [1, 2]. In contrast, in our series, MPNST constituted 12% (24/200) of all soft tissue sarcomas, with MPNST representing the second most common variety of soft tissue sarcoma seen. The most significant contributions in understanding the clinical and pathological features of MPNST were studied by Mayo clinic investigators [6, 16, 19]. A combination of gross and microscopic findings along with immunohistochemical studies is commonly used to diagnose a case of MPNST . In most instances, the tumors display fascicles of spindle cells woven into herringbone pattern with varying degrees of mitosis and necrosis. However, it is not always possible to demonstrate the origin from a nerve, especially when it arises from a small peripheral branch. This point was exemplified in a series by Nambisan et al., in which nerves could not be identified in 61% of cases of MPNST  and in the series Bilge et al., in which nerve origin could be identified only in 45–56% cases . Still, there are several other distinct features, such as proliferation of tumor in the sub-endothelial zones of vessels with nepotistic cells herniation into vessel lumen and proliferation of small vessels in the walls of the large vessels, which are very characteristic features of MPNST , as noticed in our series.
In our series, grade of the tumor emerged as the significant prognostic factor for overall survival. Likewise, cellular differentiation emerged as a significant prognostic factor for disease free survival in both univariate and multivariate analysis. However, other pathological findings, such as mitosis and tumor necrosis, had no impact on survival in our series. In our series, the index of increasing proliferation, MIB-1, was clearly correlated with grade of the tumor and simultaneously with prognosis of the disease. Ducatman et al.  reported that tumor grade and mitotic count were of no prognostic utility, while Enzinger et al.  noticed that grade of the tumor, necrosis, vascular invasion, and presence of mitosis have significant influence on survival of the patient. We have 21% of patients who have heterotrophic pathological features of the tumor; however, such divergent differentiation did not affect the survival (Table 2). In contrast, Ramanathan et al.  and Scheithauer et al.  have reported the divergent differentiation as a significant adverse prognostic marker for MPNST in their series.
These tumors occur with equal frequency in males and females and some series have shown a female preponderance [6, 7]. However, we found a significant male preponderance (80 %) in the current study and this significantly influenced the disease free (p = 0.05), as well as overall survival (p = 0.04). But it is very difficult to draw any conclusion about sex as significant prognostic factor due to small series and it may be due to referral bias. As far as the site distribution was concerned. The majority had involvement of the extremities, although tumors were also seen in unusual sites, such as the pelvic retroperitoneum and infratemporal fossa. In our series, the site of the tumor had no impact on survival of the patients (extremity versus others was p < 0.06).
The association of MPNSTs with VRHD is well known [7, 8, 23] and the series reported 5% to 42% neurofibromatosis patients develop sarcomas. In a review of 71 years experience, Ducatman et al.,  estimated that the risk of developing MPNST in VRHD to be 4600 times greater than the general population. In the current study, 21 % of patients had clinical features of VRHD, but their association did not affect the survival of the patients (Table 2), which is in contrast to the findings of other authors [1, 5, 24]. In fact, the longest surviving patient in our series was a patient having multiple neurofibromatosis who presented with 14 malignant transformations of benign neurofibromas over an 8-year period.
Routine preoperative electrophysiological examination is not integral to the management of MPNST. This is so since such an examination neither contributes to the diagnosis nor influences the treatment plan . Imaging is routinely performed to assess the extent of the disease and plan surgical resection. However, it does not reliably determine the malignant transformation from neurofibroma to MPNST . A target lesion in T2MR image is an indication of low grade while heterogenous lesion due to necrosis & hemorrhage and patchy contrast enhancement in MRI is an indication of malignant MPNST [25, 26]. MRI is the investigation of choice because it can reveal the nerve of origin and its relationship to adjacent structures . Clinical behavior of the disease with radiological correlation can also guide to plan the treatment. More importantly, we used contrast enhanced computed tomography (CECT) for assessment of pulmonary metastasis, where MRI has limitations, and also for some primary cases, when MRI was not available initially at our institute.
MPNST has the highest recurrence rate of any sarcomas , and adequate initial treatment gives the best chance of survival . In the current series, recurrence after initial treatment, whether local or metastatic, has been cited as a poor prognostic factor for overall survival (P < 0.002, Figure 7). The most important feature in present study was the nature of the disease relapse due to which even one patient could not be surgically salvaged and were treated with palliative chemotherapy.
MPNST constitutes a significant proportion of soft tissue sarcoma in our study. A combination of clinical, pathological, and immunohistochemistry helps in diagnosing these tumors. Proliferation marker (MIB1) can be a good adjunct to grade and tailor the treatment in MPNST. The overall treatment approach should be like that of any other high grade sarcomas. Heterogeneous differentiation and multifocality of the tumor were few distinct features of MPNST in our series. Sex and cellular differentiation emerged as the new adverse prognostic factors for survival of the patients, where as VHRD association had no impact on survival in our study. Postoperative radiotherapy has a definite role in both disease free and overall survival. Though multimodality therapy, including surgical resection and adjuvant radiotherapy, is available, the prognosis remains dismal. Modern clinical studies and the development of effective targeted chemotherapy are needed to gain control of the disease.
We are thankful Dr. Rajbir Singh (Scientist Gr-II) in the department of Biostatistics at All India Institute of Medical Sciences for helping in the statistical analysis and interpretation of data in the manuscript. We are also thankful to Mr. Islam, in the record keeping department at Institute Rotary Cancer Hospital, for helping us to get the patient's records for acquisition of data.
- Hruban RH, Shiu MH, Senie RT, Woodruff JM: Malignant peripheral nerve sheath tumors of the buttock and lower extremity A study of 43 cases. Cancer. 1990, 66: 1253-1265. 10.1002/1097-0142(19900915)66:6<1253::AID-CNCR2820660627>3.0.CO;2-R.View ArticlePubMed
- Angelov L, Guha A: Peripheral Nerve Tumors. Neuro oncology Essentials. Edited by: Berstein M, Berger MS. 2000, New York Theme Publishers, 434-444. 1
- Wanebo JE, Malik JM, VandenBerg SR, Wanebo JH, Driesen N, Persing JA: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer. 1993, 71: 1247-1253. 10.1002/1097-0142(19930215)71:4<1247::AID-CNCR2820710413>3.0.CO;2-S.View ArticlePubMed
- Dasgupta TK, Choudhuri PK: Tumors of soft tissue. 1998, Connecticut Appleton & Lange, 127-395. 2
- Ducatman SB, Bernd WS, David GP, Herbert MR, Duane MI: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986, 57: 2006-2021. 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6.View ArticlePubMed
- D'Agostino AN, Soule EH, Miller RH: Sarcoma of the peripheral nerves & somatic soft tissues associated with multiple neurofibromatosis (Von Recklinghausen's disease). Cancer. 1963, 16: 1015-1027. 10.1002/1097-0142(196308)16:8<1015::AID-CNCR2820160808>3.0.CO;2-I.View ArticlePubMed
- Cashen DV, Parisien RC, Raskin K, Hornicek FJ, Gebhardt MC, Mankin HJ: Survival data for patients with malignant schwannoma. Clin Orthop Relat Res. 2004, 426: 69-73. 10.1097/01.blo.0000131256.82455.c5.View ArticlePubMed
- Hirose T, Scheithauer BW, Sano T: Perineural malignant peripheral nerve sheath Tumour (MPNST) – A clinicopathologic, immunohistochemical and ultrastructural study of seven cases. Am J Surg Pathol. 1998, 22: 1368-1378. 10.1097/00000478-199811000-00007.View ArticlePubMed
- Stout AP: Tumors of peripheral nervous system: Atlas of tumor pathology, Sect. 2, fasc. 6. 1949, Washington, D.C, Armed forces Institute of pathology
- Brasfield RD, Das Gupta TK: Von Recklinghausen's disease: A clinicopathological study. Ann Surgery. 1972, 175: 86-104.View Article
- Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A: Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Med Genet. 2002, 39: 311-314. 10.1136/jmg.39.5.311.PubMed CentralView ArticlePubMed
- Nambisan RN, Rao U, Moore R, Karakousis CP: Malignant soft tissue tumors of nerve sheath origin. J Surg Oncol. 1984, 25: 268-272.View ArticlePubMed
- Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002, 62: 1573-1577.PubMed
- Angelov L, Davis A, O'Sullivan B, Bell R, Guha A: Neurogenic sarcomas: experience at the University of Toronto. Neurosurg. 1998, 43: 56-64. 10.1097/00006123-199807000-00035. discussion 64–65View Article
- Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988, 45: 575-578.
- Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C: Soft tissue sarcomas in adults. Study of pathological prognostic variables and definition of histological grading system. Int J Cancer. 1984, 33: 37-42.View ArticlePubMed
- Yamaguchi U, Hasegawa T, Chuman H, Kawai A, Ito Y, Beppu Y: Low grade malignant peripheral nerve sheath tumor: varied cytological and histological patterns. J clin Pathol. 2003, 56: 826-830. 10.1136/jcp.56.11.826.PubMed CentralView ArticlePubMed
- Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, Viscochil DH: Malignant nerve sheath tumor: A comparision of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis1-related lesions. Am J Surg Pathol. 2003, 27: 1337-1345.View ArticlePubMed
- Wick M, Swanson P, Scheithauer B, Manivel JC: Malignant peripheral nerve sheath tumor, an immunohistochemical study of 62 cases. Am J Clin Pathol. 1987, 87: 425-433.PubMed
- Bilge B, Ates LE, Demiryont M, Ozger H, Dizdar Y: Malignant peripheral nerve sheath tumors associated with neurofibromatosis Type 1. Pathol Oncol Res. 2003, 9: 201-205.View Article
- Weiss SW, Goldblum JR: Soft Tissue Tumors. 2001, St. Louis Mosby Co, 1209-1263. 4
- Ramanathan RC, Thomas JM: Malignant peripheral nerve sheath tumor associated with von Reckling Hausen's neurofibromatosis. Eur J Surg Oncol. 1999, 25: 190-193. 10.1053/ejso.1998.0625.View ArticlePubMed
- Scheithauer BW, Woodruff JM, Erlandson RA: Tumors of the peripheral Nervous system. Atlas of Tumor Pathology, 3rd Series, fascicle 24. 1999, Washington, DC: Armed Forces Institute of Pathology, 303-369.
- Preston FW, Walsh WS, Clarke TH: Cutaneous Neurofibromatosis (Von Reckling Hausen's disease: clinical manifestations and incidence of sarcoma in 61 male patients. AMA Arch Surgery. 1952, 64: 813-827.View Article
- Bhargava R, Parham DM, Lasater OE, Chari RS, Chen G, Fletcher BD: MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign. Pediatr Radiol. 1997, 27: 124-129. 10.1007/s002470050082.View ArticlePubMed
- Friedrich RE, Kluwe L, Funsterer C, Mautner VF: Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1) diagnostic findings on magnetic resonance images and mutational analysis of the NF1 gene. Anticancer Res. 2005, 25 (3A): 1699-1702.PubMed
- Suh JS, Abenoza P, Galloway HR, Everson LI, Griffiths HJ: Peripheral (extra cranial) nerve tumors: Correlation of MR imaging and histological findings. Radiology. 1992, 183: 341-346.View ArticlePubMed
- Ghosh BC, Ghosh L, Huvos AG, Fortner JG: Malignant schwannoma A clinicopathologic study. Cancer. 1973, 31: 184-190. 10.1002/1097-0142(197301)31:1<184::AID-CNCR2820310126>3.0.CO;2-8.View ArticlePubMed
- Basso-Ricci S: Therapy of malignant schwannomas: usefulness of an integrated radiologic. surgical therapy. J Neurosurg Sci. 1989, 33: 253-257.PubMed
- Collin C, Godbold J, Hajdu S, Brennan M: Localized extremity soft tissue sarcomas an analysis of factors affecting survival. J Clin Oncol. 1987, 5: 601-612.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.